A phase II trial of the effect of perindopril on hand–foot skin reaction (HFSR) incidence and severity in patients receiving regorafenib for refractory mCRC
暂无分享,去创建一个
S. Gill | C. Kollmannsberger | B. Melosky | D. Renouf | J. Davies | M. Ho | H. Lim | Solomon A. Vandt